Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
There is no consensus on the treatment of patients with recurrent infections and isolated
immunoglobulin G (IgG)-subclass deficiency and/or selective antipolysaccharide antibody
deficiency. Therefore, the Dutch Inter University Working Party will start a study in which
the treatment with antibiotics is compared with intravenous immunoglobulin therapy with
respect to clinical outcome measures in both children and adults with this disorder.